- Little Green Pharma gets extended contract from the French government
- US FDA’s decision paves the way for a clinical involving Immuron’s drug
- Antisense Therapeutics announces new CEO
Cannabis stock Little Green Pharma (ASX:LGP) has been re-appointed as a primary supplier of its 1:20 THC:CBD medicinal cannabis oil to the extended French national medicinal cannabis trial.
The announcement has reaffirmed LGP’s commitment to France, one of the largest EU markets critical to LGP’s EU strategy – giving LGP a first mover advantage in the country.
The trial has already shown beneficial clinical outcomes over its first two years, with 91% of the current 1,453 patients reporting positive results.
To date, LGP has supplied its 1:20 THC:CBD and CBD50 oils to patients in the trial, becoming a well-recognised supplier in the French market in the process.
Following the trial’s initial success, the French government had proposed to extend the trial for a third year, until March 2024.
Data from the study will become one of the largest European data collections on cannabis, with the success of the trial already generating calls by patient associations for the legalisation of medicinal cannabis as soon as possible.
The French medicinal cannabis is said to have a total addressable market of up to €5.6 billion.
US FDA’s decision paves way for Immuron
The US FDA has removed the clinical hold on its New Campylobacter ETEC Therapeutic IND application, paving the way for a clinical trial involving Immuron’s (ASX:IMC) drug.
This comes after the US Naval Medical Research Center (NMRC) received an approval from the FDA to proceed with the clinical evaluation of a new oral therapeutic targeting Campylobacter and Enterotoxigenic Escherichia coli (ETEC), developed in collaboration with Immuron.
The first trial will evaluate infectious diarrhoea caused by Campylobacter and ETEC. A second trial meanwhile will focus on protecting volunteers against moderate to severe campylobacteriosis.
The study population will include 30 healthy participants (males or non-pregnant, non-nursing females), aged 18-50 years. Commencement is subject to ethics approval from the Institutional Review Board.
Infectious diarrhoea is the most common illness reported by travellers visiting developing countries and among US troops deployed overseas.
A preventative treatment that protects against enteric diseases is a high priority objective for the US Military.
Antisense appoints Kazia’s ex CEO
Antisense Therapeutics (ASX:ANP) announced the appointment of Dr James Garner as CEO and managing director, effective 7 August.
He replaces Mark Diamond who announced his retirement in November last year.
Dr Garner’s previous experience include leading Phase I-IV clinical trials, product registration, reimbursement, and business development.
He has has a 20-year career in the pharmaceutical/biotech industry including with companies such as Biogen, Progen Pharmaceuticals, Quintiles, and as Head of the Unit Development with Sanofi in Singapore.
Most recently, Dr Garner served as CEO of Kazia Therapeutics (ASX:KZA; NASDAQ:KZIA), a dual-listed clinical-stage, oncology-focused company.
Share prices today: